Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2022) Jie Wang et al.   LANCET ONCOLOGY

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

(2022) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

(2021) Stephen V. Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

(2021) D.R. Spigel et al.   ANNALS OF ONCOLOGY

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

(2021) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups

(2021) Francesco Passiglia et al.   Translational Lung Cancer Research

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

(2020) A.S. Mansfield et al.   ANNALS OF ONCOLOGY

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small-cell lung cancer

(2020) Dawei Chen et al.   Cancer Immunology Research

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial

(2020) Davey Daniel et al.   INTERNATIONAL JOURNAL OF CANCER

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

(2020) Jonathan W Goldman et al.   LANCET ONCOLOGY

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

(2020) Suchita Pakkala et al.   Journal for ImmunoTherapy of Cancer

The Future of Immunotherapy in the Treatment of Cancer

(2019) Lisa A. Kottschade   Seminars in Oncology Nursing

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

(2019) J M Weiss et al.   ANNALS OF ONCOLOGY

1736OIMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

(2019) M Reck et al.   ANNALS OF ONCOLOGY

Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer

(2019) James W. Welsh et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

(2018) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

(2018) Gregory P. Kalemkerian et al.   Journal of the National Comprehensive Cancer Network

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells

(2017) Irina Kareva   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Targeting Immune Checkpoints in Cancer Therapy

(2017) Suzanne L. Topalian   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Consolidative thoracic radiotherapy for extensive stage small cell lung cancer

(2017) Xiaoli Zhang et al.   Oncotarget

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

(2016) Edurne Arriola et al.   Journal of Thoracic Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

(2016) Joohee Sul et al.   ONCOLOGIST

Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

(2015) Ben J Slotman et al.   LANCET

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression

(2014) liufu deng et al.   OncoImmunology

Advances in targeting cell surface signalling molecules for immune modulation

(2013) Sheng Yao et al.   NATURE REVIEWS DRUG DISCOVERY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Impact of minimal tumor burden on antibody response to vaccination

(2011) Soo-Kie Kim et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Small-cell lung cancer

(2011) Jan P van Meerbeeck et al.   LANCET

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

(2009) O. Klein et al.   CLINICAL CANCER RESEARCH